Systematic identification of small molecule adjuvants

Area of Science:

• Vaccinology
• Immunology
• Medicinal Chemistry

Background:

• Adjuvants boost vaccine immunogenicity, reducing antigen dose and frequency.
• Current licensed adjuvants (alum, oil-in-water) have limitations.
• Small molecule adjuvants (SMAs) represent a promising alternative class.

Purpose of the Study:

• To review the current status of small molecule adjuvants (SMAs).
• To highlight the potential for systematic discovery and rational optimization of SMAs.
• To discuss the mechanisms and discovery of SMAs.

Main Methods:

• Focus on small molecules acting as adjuvants.
• Review of known SMAs including natural products, oligonucleotides, and synthetic molecules.
• Exploration of high-throughput discovery methods for SMAs.

Main Results:

• SMAs, especially synthetic ones, are highly optimizable using drug-discovery techniques.
• Computational approaches like QSAR and structure-based design enable rational optimization.
• Properties can be tailored for specific cellular targets and pathways.

Conclusions:

• Synthetic drug-like SMAs are amenable to optimization via established drug-discovery methods.
• Rational design allows tailoring SMAs for specific biological functions and disease targets.
• SMAs offer a powerful platform for developing next-generation vaccines with improved efficacy and specificity.